Prosecution Insights
Last updated: November 10, 2026
Application No. 17/718,575

FIBER SCAFFOLDS FOR USE CREATING IMPLANTABLE STRUCTURES

Non-Final OA §103§112§DP
Filed
Apr 12, 2022
Priority
Sep 25, 2013 — provisional 61/882,504 +2 more
Examiner
PIPIC, ALMA
Art Unit
1617
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Nfs Ip Holdings LLC
OA Round
5 (Non-Final)
55%
Grant Probability
Moderate
5-6
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 55% of resolved cases
55%
Career Allowance Rate
399 granted / 729 resolved
-5.3% vs TC avg
Strong +54% interview lift
Without
With
+54.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
50 currently pending
Career history
775
Total Applications
across all art units

Statute-Specific Performance

§101
0.8%
-39.2% vs TC avg
§103
44.0%
+4.0% vs TC avg
§102
7.6%
-32.4% vs TC avg
§112
31.6%
-8.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 729 resolved cases

Office Action

§103 §112 §DP
--DETAILED ACTION-- Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant’s submission filed on September 11, 2026 has been entered. Priority This application is a continuation of 15/631,387 filed on 06/23/2017, which is a continuation of 14/496,070 filed on 09/25/2014, and claims benefit in provisional application 61/882,504 filed on 09/25/2013. Claim Status Claims 1, 3, 15, and 25-27 are pending and examined. Claims 25-27 were newly added and read on the invention originally presented. Claims 2, 4-14, and 16-24 were canceled. Claims 1, 3, and 15 were amended. In the interest of compact prosecutions, the claims are treated on the merits. However, it is noted that claims submitted on 09/11/2026 do not comply with 37 CFR 1.121 because claim 15 has the status identifier “Previously Presented” and the claim was amended by deleting text and adding new text. Withdrawn Claim Rejections - 35 USC § 103 Rejections of claims 1 and 11-13 over El-Kurdi (WO 2008/094971 A2 Published August 7, 2008) and rejections of claims 1, 3, 11-13, 15, and 17-19 over Anneaux (US 2011/0030885 Al Published February 10, 2011 - of record in IDS dated 05/10/2022) and El Kurdi are withdrawn because claim 1 was amended to require the scaffold to consist of two layers of electrospun fibers, which is not obvious over El-Kurdi or Anneaux because El-Kurdi teaches an implant that is required to have a tubular tissue wrapped with an electrospun fiber matrix; and Anneaux teaches a device having a single layer of electrospun fibers where the fibers are randomly oriented. Withdrawn Double Patenting Rejections Rejections of claims 1, 15, and 17 over claims 1-11 of U.S. Patent No. 9,737,632 B2 (of record in IDS dated 05/10/2022) in view of Anneaux and El Kurdi are withdrawn because patented claims require a scaffold that is limited to a single layer, whereas instant claims require two layers. It would not have been obvious to modify patented claims to arrive at the instantly claimed invention. Rejections of claims 1, 3, 11-13, 15, and 17-19 over claims 1-13 of U.S. Patent No. 10,233,427 B2 in view of Anneaux and El Kurdi are withdrawn because it would not have been obvious to modify the implant in patented claims to arrive at the instantly claimed scaffold, with a reasonable expectation of success. One of skill in the art would not have been motived to modify the patented implant by adding a second layer having a fiber orientation as claimed. Rejections of claims 1, 3, 11-13, 15, and 17-19 over claims 1-54 of U.S. Patent No. 12,167,853 B2 in view of Anneaux and El Kurdi are withdrawn because instant claims were amended and the rejection no longer requires Anneaux and El Kurdi. Rejections of claims 1, 3, 11-13, 15, and 17-19 over claims 1-43 of U.S. Patent No. 10,227,568 B2 in view of Anneaux and El Kurdi are withdrawn because instant claims were amended and the rejection no longer requires Anneaux and El Kurdi. Claim Objections Claim 1 is objected to because it ends with a comma and a period. Appropriate correction is required. Claim Rejections – 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1, 3, 15, and 25-27 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Claims 1 and 25 require a scaffold consisting of a first layer of electrospun polymer fibers having an orientation relative to one another that is generally parallel, and a second layer of electrospun polymer fibers having an orientation relative to one another that is generally random. In the remarks dated 09/11/2026, applicant cited paragraphs 0023, 0025, and 0032 for support of the newly added limitations. The claims introduce new matter because the application as filed does not provide support for a scaffold consisting of two layers. Paragraph 0023 teaches one or more layers. Paragraph 0025 does not mention a number of layers in the scaffold. Paragraph 0032 teaches a scaffold made from a single layer or a composite comprising layers. Paragraph 0035 teaches a tri-layered tube. Applicant is requested to clarify how the application as filed provides support for the specific embodiment of a scaffold consisting of two layers as described by the claims. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CPR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claims 1 and 25 are rejected under 35 U.S.C. 103 as being unpatentable over Li (US 2007/0269481 A1 Published November 22, 2007 – of record in IDs dated 05/10/2022). The claims encompass a scaffold consisting of a first layer of electrospun polymer fibers having an orientation relative to one another that is generally parallel, and a second layer of electrospun polymer fibers having an orientation relative to one another that is generally random, wherein the scaffold has a conduit shape. The teachings of Li are related to biomimetic scaffolds (Abstract). The scaffolds are useful for treating injured nerves (paragraph 0007). Paragraph 0114 teaches polymers that are suitable for making the scaffolds. The fibers are produced by electrospinning methods (paragraph 0118). In one embodiment, a seamless fibrous polymer scaffold conduit is formed with an inner wall composed of longitudinally aligned fibers and an outer wall composed of unaligned fibers (paragraphs 00167 and 00170). It would have been prima facie obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to have formed a scaffold in the shape of a conduit wherein the scaffold consists of an inner wall composed on longitudinally aligned fibers and an outer wall composed of unaligned fibers, with a reasonable expectation of success because Li teaches a scaffold in the shape of a conduit wherein the scaffold is created with an inner wall composed on longitudinally aligned fibers and an outer wall composed of unaligned fibers. Li’s conduit is described as having two layers, therefore the conduit consist of a first layer and a second layer as required by the claims. It would have been obvious to have formed the layers by electrospinning because Li teaches electrospinning as a suitable method of making the fibers (paragraph 0166). The inner wall composed of longitudinally aligned fibers reads on the first layer of electrospun polymer fibers having an orientation relative to one another that is generally parallel. Figures 8 and 12B depict longitudinally aligned polymer scaffold sheet and it is apparent that fibers are aligned parallel to one another. The outer wall composed of unaligned fibers reads on the second layer of electrospun polymer fibers having an orientation relative to one another that is generally random. Figure 12 A depicts unaligned fibers and it is apparent from the drawing that fibers are randomly oriented. The limitation “wherein the electrospun polymer fibers are formed as drug eluting fibers” in claim 25 is obvious because Li’s scaffold meets all of the structural limitations of instantly claimed scaffold and could have been used as drug eluting fibers absent evidence to the contrary. Additionally, Li teaches that the conduit is suitable for delivering biomolecules such as growth factors (paragraph 0202). Claims 3 and 26 are rejected under 35 U.S.C. 103 as being unpatentable over Li as applied to claims 1 and 25 above, and further in view of Li (“Li ‘204” US 2003/0028204 A1 Published February 6, 2003). The claims further define the scaffold of claims 1 and 25. The teachings of Li are relied upon as summarized above, however Li does not teach the limitations of claims 3 and 26. The teachings of Li ‘204 are related to an implant device including a tubular matrix made of a biocompatible and bioresorbable biopolymeric material. The matrix has a first end and a second end, a wall of a homogeneous thickness; a plurality of ridges on the wall; and a channel which is defined by the wall and extends from the first end to the second end of the tubular matrix (Abstract). Further, although these devices are tubular, they do not all provide kink resistance. Kink resistance (i.e., resistance to forming a crease or a sharp bending of the wall) is particularly important in cases which require bending of the device for proper connections, such as nerve repairs in wrists and hands. Kinking of a nerve-guiding tube causes nerve compression and potential axonal disruption and neuroma formation (paragraph 0005). Therefore, there is a need for a biocompatible, resorbable, semipermeable, and kink resistant tubular implant for nerve repair (paragraph 0008). Paragraph 0014 teaches how the ridged tubular matrix is formed. The ridges on the wall provide flexibility in the implant, thus rendering it kink resistant (paragraph 0033). The teachings of Li and Li ‘204 are related to polymer conduits intended for treating nerves and it would have been obvious to have combined their teachings because they are in the same field of endeavor. It would have been prima facie obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to have formed Li’s conduit with ridges intended to increase kink resistance, with a reasonable expectation of success because it was known from Li ‘204 that conduits intended for nerve repair should be kink resistant because kinking of nerve guiding tube causes nerve compression and potential axonal disruption and neuroma formation. The skilled artisan would have been motivated to modify Li’s conduit in view of Li ‘204 because the modification would have improved Li’s conduit. Claims 15 and 27 are rejected under 35 U.S.C. 103 as being unpatentable over Li as applied to claims 1 and 25 above, and further in view of Anneaux. Li teaches that the fibers of the polymer scaffold have a diameter from about 0.1 nanometers to about 50,000 nanometers (paragraph 0112). Li further teaches that the polymer scaffold is nano-porous and breathable (paragraph 0208). However, Li does not teach pore size of the scaffold. The teachings of Anneaux are related to a prosthetic device formed from electrostatically spun fibrous layers (Title). Fibers are formed from polymers (paragraph 0009). Final material size varies as the composite can be produced as sheets or tubes. The composite internodal distance can be about 0.1 to about 200 microns with porosity ranging from about 20 to 90% (paragraph 0028). The teachings of Li and Anneaux are related to prosthetic devices formed from electrostatically spun fibrous layers formed from polymers and it would have been obvious to have combined them because they are in the same field of endeavor. It would have been prima facie obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to have formed Li’s scaffold as a nano-porous scaffold and from fibers having a diameter in the range of 0.1-50,000 nm, with a reasonable expectation of success because Li teaches that the scaffold is nano-porous and breathable and teaches forming the scaffold with fibers having a diameter in the range of 0.1-50,000 nm. The claimed fiber diameter of from about 100 nm to about 50 microns is obvious because it is encompassed by Li’s range of diameters. Li does not provide a range of suitable pore sizes of the scaffold. It would have been obvious to have formed the scaffold having a range of pore sizes from about 0.1 to about 200 microns because Anneaux teaches said range as suitable in tube shaped prosthetic devices formed from fibers obtained by electrospinning polymers. The claimed pore size range is obvious because it overlaps with Anneaux’ range. Double Patenting Rejections The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 3, 15, and 25-27 are rejected on the ground ofnonstatutory double patenting as being unpatentable over claims 1-54 of U.S. Patent No. 12,167,853 B2 in view of Li ‘204. Patented claims are drawn to a resorbable hybrid-scale fiber matrix for use in facilitating nerve repair and regeneration, the matrix comprising: an inner fiber layer comprising uniaxially aligned or longitudinally-aligned fibers; and an outer fiber layer comprising randomly-aligned fibers, wherein the hybrid-scale fibers comprise fibers having a range of fiber diameters between 10 nm-10,000 nm (claim 1), wherein a mean pore size of the matrix is less than 300μ.sup.2. (claim 18), wherein the matrix comprises a shape geometry of a conduit (claim 16), and wherein the hybrid-scale fibers comprising a resorbable polymer selected from a group of polymers consisting of polycaprolactone, poly lactic acid, and polyglycolic acid (claim 17). Limitations of claims 1 and 25 are obvious over patented claims because patented claims are drawn to a nerve repair construct that comprises a inner fiber layer and an outer fiber layer that meet the limitations of the instantly claimed first and second layers. Patented fibers could have been used for delivering a drug, absent evidence to the contrary. Regarding claims 3 and 26, it would have been obvious to have formed the patented scaffold with ridges because having ridges in a vascular graft was known from Li ‘204. Regarding claims 15 and 27, the claimed diameter range is obvious because it overlaps with the patented diameter range in claim 2. The claimed pore size range is obvious because it overlaps with less than 300 microns. Claims 1, 3, 15, and 25-27 are rejected on the ground ofnonstatutory double patenting as being unpatentable over claims 1-43 of U.S. Patent No. 10,227,568 B2 in view of Li ‘204. Patented claims are drawn to an implantable artificial organ comprising: a scaffold comprising at least one layer of electrospun fibers having an orientation, a diameter, and a fiber spacing configured to control the orientation, growth, or differentiation of biological cells seeded thereon, the scaffold formed into a replica of a biological organ selected from the group consisting of an esophagus, a small intestine, a large intestine, a duodenum, and a jejunum; wherein the scaffold has an interior surface that is smooth on the microscale; wherein the electrospun fibers comprise a radiopaque material; and wherein the electrospun fibers have a fiber spacing of about 2 micrometers to about 50 micrometers (claim 1), wherein the electrospun fibers comprise one or more of a polycaprolactone, a poly lactic acid, and a polyglycolic acid (claim 3), wherein the electrospun fibers have a diameter from about 100 nanometers to about 1000 nanometers (claim 4), wherein the electrospun fibers have an orientation selected from the group consisting of substantially mutually parallel, randomly oriented, and a combination thereof (claim 7), wherein the electrospun fibers comprise a mixture of multiple materials (claim 9), wherein the electrospun fibers further comprise one or more of an elutable drug (claim 10). The implantable artificial organ of claim 1, wherein the at least one layer of electrospun fibers comprises a plurality of layers of electrospun fibers (claim 11), wherein the electrospun fibers of at least one layer of the plurality of layers of electrospun fibers comprise a first material, and the electrospun fibers of at least a second layer of the plurality of layers of electrospun fibers comprise a second material (claim 13), wherein the electrospun fibers of at least one layer of the plurality of layers of electrospun fibers have a first orientation, and the electrospun fibers of at least a second layer of the plurality of layers of electrospun fibers have a second orientation (claim 17). Regarding claims 1 and 25, it would have been obvious to have formed a scaffold having two layers, each layer formed from electrospun polymer fibers and wherein the two layers having different fiber orientation, with a reasonable expectation of success because patented claims encompass an embodiment that meets these limitations. Patented claims teach fiber orientation that is parallel and random, thus it would have been obvious to form one layer having parallel fibers and the second layer having randomly oriented fibers because patented claims include an embodiment where the first and second layers have different fiber orientation. Patented claims teach that implant is a replica of tube shaped organs thus it would have been obvious to have formed the implant having a conduit shape. The claimed fiber diameter and scaffold pore size are obvious because claimed ranges overlap with the corresponding parameters in the patented claims. Regarding claims 3 and 26, it would have been obvious to have formed the patented scaffold with ridges because having ridges in tubular grafts was known from Li ‘204 in order to reduce kink formation. Regarding claims 15 and 27, the claimed diameter range is obvious because it overlaps with the patented diameter range in claims 4 and 5. The claimed pore size range is obvious because it overlaps with the range of 2 microns to 50 microns. Fiber spacing in the patented claims reads on pore size. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alma - Pipic whose telephone number is (571)270-7459. The examiner can normally be reached M-F 9:00am-5:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://v-/w,v.uspto.gov/intervie'vvpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hartley can be reached on 571- 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ALMA PIPIC/Primary Examiner, Art Unit 1617
Read full office action

Prosecution Timeline

Show 5 earlier events
Dec 17, 2025
Request for Continued Examination
Dec 22, 2025
Response after Non-Final Action
Dec 29, 2025
Non-Final Rejection mailed — §103, §112, §DP
May 28, 2026
Response Filed
Jun 11, 2026
Final Rejection mailed — §103, §112, §DP
Sep 11, 2026
Request for Continued Examination
Sep 13, 2026
Response after Non-Final Action
Sep 16, 2026
Non-Final Rejection mailed — §103, §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12745771
METHODS OF CONTROLLING OR PREVENTING INFESTATION OF SOYBEAN PLANTS BY PHYTOPATHOGENIC MICROORGANISMS
5y 2m to grant Granted Sep 29, 2026
Patent 12740942
SURFACE TREATMENT OF CONTACT LENS AND TREATMENT OF OCULAR DISCOMFORT BY WATER SOLUBLE POLYMERS AND LIPIDS/LIPOSOMES
2y 7m to grant Granted Sep 22, 2026
Patent 12728006
BIOCOMPATIBLE STRUCTURE, AND FABRICATING METHODS AND APPLICATIONS OF SAME
4y 0m to grant Granted Sep 08, 2026
Patent 12691066
DUAL-TARGETING BIOMIMETIC LIPOSOME WITH ELEMENE (ELE) AND CABAZITAXEL (CTX), AND PREPARATION METHOD AND USE THEREOF
2y 5m to grant Granted Jul 28, 2026
Patent 12679785
Microbe-Based Products for Enhancing Plant Root and Immune Health
3y 11m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
55%
Grant Probability
99%
With Interview (+54.2%)
3y 1m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 729 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month